Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

Studies to be presented will include:

* A Phase 2, 185-patient randomized, placebo-controlled, dose-

escalation study in bunionectomy surgeries, which demonstrated

statistically significant reductions in average and worst pain scores

in the 1 mg Adlea dose group compared to placebo. In addition,

patients in the 1 mg Adlea group had a statistically significantly

longer median time to first use of an opioid or another acute pain

treatment compared to placebo. This Phase 2 trial is the basis for

the ongoing Phase 3 Adlea trial in bunionectomy surgeries, which

compares the same 1 mg Adlea dose to placebo control; the primary

endpoint in both trials is reduction in pain up to 32 hours post-

surgery for Adlea versus placebo.

* An exploratory clinical study in painful osteoarthritis of the knee

in which Adlea was generally well-tolerated, particularly when

stepwise dosing was used to reduce pain on injection in this non-

surgical setting. The study also generated longer-term data

suggesting reduced pain scores compared to baseline for up to the

eight week study endpoint.

* An independent presentation on long-term follow up from a study in

herniotomy surgeries which showed that, two years post-surgery, Adlea

treatment did not differ from placebo with regard to long-term

effects on sensory function in the surgical area.

* Preclinical studies suggesting that a single, clinically relevant

dose of Adlea does not have observable adverse effects on wound and

bone healing. A separate preclinical study demonstrated that a single

dose of Adlea caused a prolonged decrease in specific neuronal

markers and the TRPV1 receptor, suggestive of desensitization of the

nerve fibers, which gradually reversed
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2
... MISSISSAUGA, ON, Oct. 22 /PRNewswire-FirstCall/ - YM BioSciences ... an oncology company that identifies,develops and commercializes differentiated ... of Directors has adopted a renewed,Shareholder Rights Plan ... fair treatment of shareholders in connection with any ...
... Call and Webcast to Follow, THE WOODLANDS, Texas, ... will release its third quarter 2007,financial results on Tuesday, ... will hold a conference call to discuss the,company,s results ... at 5:00 p.m. Eastern Time on October 30, 2007. ...
... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... announced that it has signed a definitive purchase,agreement ... Inc.,for a purchase price of $5.6 million in ... Cellmark restricted common stock. The purchase price is,subject ...
Cached Biology Technology:YM Biosciences announces adoption of renewed Shareholders' Rights Plan 2YM Biosciences announces adoption of renewed Shareholders' Rights Plan 3Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007 2Orchid Cellmark to Purchase ReliaGene Technologies, Inc. 2Orchid Cellmark to Purchase ReliaGene Technologies, Inc. 3
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... to Wednesday, Oct. 18-22, 2014 , WHERE: ... Drive, San Diego, CA 92101 , WHAT: ... presentations of the latest research in human genetics. ... featuring high-scoring abstracts on rare genetic variants in ... and treatment for sun sensitivity (Saturday, Oct. 18, ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... moss on a tree trunk always points north. According to ... may also provide a new "compass" for stem cell research, ... purposes. Dr. Nir Ohad of Tel Aviv ... the University of Freiburg have discovered a new use for ...
... a lot from an animal. By manipulating the DNA of ... deal about the genes and molecules behind many of life,s ... in people as they do in "model" animals. But if ... humans, ability to learn language from one another, you need ...
... of the research was to gather information on the effects ... and dynamic characteristics of plankton in the estuaries. The ... work entitled Impact of climate variability on the pelagic ecosystem ... Biscay): a time series analysis. He has studied the estuaries ...
Cached Biology News:Telltale moss 2Transgenic songbirds provide new tool to understand the brain 2University of Basque Country research study on effects of climate on plankton in the estuaries 2
... The European Collection of Cell Cultures (ECACC) ... West of the West of England, Bristol, ... the quality control of HER2, oestrogen and ... paraffin wax sections of formalin fixed, breast ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
...
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
Biology Products: